Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion

Understanding the basic mechanisms of drug interactions allows ­researchers and clinicians to best interpret and apply drug interaction data, and make predictions about patient-specific interactions. Drug interactions can occur at the site of action (pharmacodynamic interactions), and during the absorption, ­distribution, metabolism and excretion phases of drug distribution (pharmacokinetic interactions). The consequences of unintended interactions can be extremely harmful and potentially fatal, such as those leading to cardiac conduction abnormalities. Knowledge of the mechanisms of drug interactions has also identified ­useful interactions with therapeutic benefits, such as in the development of feasible dosing regimens for protease inhibitors in the treatment of HIV infection. This chapter describes the mechanisms of drug interactions for each of the aforementioned pharmacokinetic processes. The cytochrome P450 family of enzymes, the P-glycoprotein drug transporter, and their mechanisms for inhibition, induction, and suppression are reviewed. Preclinical methods used to study cytochrome P450 are discussed. The chemical and physiologic changes that affect absorption and elimination, and how they are influenced by drugs, are explained.

[1]  R. Weinshilboum,et al.  Olsalazine and 6‐mercaptopurine‐related bone marrow suppression: A possible drug‐drug interaction , 1997, Clinical pharmacology and therapeutics.

[2]  W. Reiss,et al.  Changes in Interleukin-6 Concentrations following Epilepsy Surgery: Potential Influence on Carbamazepine Phannacokinetics , 1996, The Annals of pharmacotherapy.

[3]  S. Arfin,et al.  The sequence of porcine protein NH2-terminal asparagine amidohydrolase. A new component of the N-end Rule pathway. , 1995, The Journal of biological chemistry.

[4]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[5]  Hongbing Wang,et al.  Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.

[6]  P. Watkins,et al.  Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[7]  R. Weinshilboum,et al.  Erratum: Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction (Clinical Pharmacology and Therapeutics (1997) 62 (464-475)) , 2000 .

[8]  D. Shen,et al.  Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[9]  M. Nikolova-Karakashian,et al.  Regulation of Cytochrome P450 2C11 (CYP2C11) Gene Expression by Interleukin-1, Sphingomyelin Hydrolysis, and Ceramides in Rat Hepatocytes (*) , 1995, The Journal of Biological Chemistry.

[10]  L. Harries,et al.  Molecular genetics of the human cytochrome P450 monooxygenase superfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  R. Gugler,et al.  Effects of Antacids on the Clinical Pharmacokinetics of Drugs , 1990, Clinical pharmacokinetics.

[12]  R. Stewart,et al.  Clinically desirable drug interactions. , 1985, Annual review of pharmacology and toxicology.

[13]  K. Carroll,et al.  Influence of extracellular matrix overlay and medium formulation on the induction of cytochrome P-450 2B enzymes in primary cultures of rat hepatocytes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[14]  I. Yano,et al.  Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1. , 1998, The Journal of pharmacology and experimental therapeutics.

[15]  C. Peloquin,et al.  Effect of Grapefruit Juice on Clarithromycin Pharmacokinetics , 1998, Antimicrobial Agents and Chemotherapy.

[16]  R. Woosley,et al.  Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.

[17]  S. Levy,et al.  The challenge of antibiotic resistance. , 1998, Scientific American.

[18]  S. Jamieson,et al.  Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. , 1985, Transplantation.

[19]  C. Metroka,et al.  Failure of prophylaxis with dapsone in patients taking dideoxyinosine. , 1991, The New England journal of medicine.

[20]  P. Beaune,et al.  The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes. , 1995, Gastroenterology.

[21]  R. Yumoto,et al.  Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. , 1998, European journal of pharmacology.

[22]  H. Lipp,et al.  Assessment of biological activities of mixtures of polychlorinated dibenzo-p-dioxins (PCDDs) and their constituents in human HepG2 cells , 2005, Archives of Toxicology.

[23]  K. Chan,et al.  Decrease in the activity of the drug-metabolizing enzymes of rat liver following the administration of tilorone hydrochloride. , 1976, Drug metabolism and disposition: the biological fate of chemicals.

[24]  P. Ghezzi,et al.  Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice. , 1995, European journal of pharmacology.

[25]  Cheng Cheng,et al.  MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype , 2006, Clinical pharmacology and therapeutics.

[26]  T. Vales,et al.  Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. , 1994, Biochimica et biophysica acta.

[27]  E. Tanaka,et al.  Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.

[28]  J. Kampmann,et al.  Effect of some drugs on penicillin half‐life in blood , 1972, Clinical pharmacology and therapeutics.

[29]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.

[30]  H K Kroemer,et al.  "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.

[31]  J. Huneau,et al.  Secretion of Sparfloxacin from the Human Intestinal Caco-2 Cell Line Is Altered by P-Glycoprotein Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.

[32]  J. Hayes,et al.  Regulation of glutathione S-transferases and aldehyde reductase by chemoprotectors: studies of mechanisms responsible for inducible resistance to aflatoxin B1. , 1996, IARC scientific publications.

[33]  R. Quintiliani,et al.  Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. , 1990, Diagnostic microbiology and infectious disease.

[34]  J. Alsenz,et al.  Active Apical Secretory Efflux of the HIV Protease Inhibitors Saquinavir and Ritonavir in Caco-2 Cell Monolayers , 1998, Pharmaceutical Research.

[35]  L. Chauvelot‐Moachon,et al.  Acute‐phase response, interleukin‐6, and alteration of cyclosporine pharmacokinetics , 1994, Clinical pharmacology and therapeutics.

[36]  S. Sassa,et al.  Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. , 1992, Biochemical and biophysical research communications.

[37]  C. Fletcher,et al.  The Effect of Cimetidine and Ranitidine Administration With Zidovudine , 1995, Pharmacotherapy.

[38]  D. Greenblatt,et al.  Drug interactions with grapefruit juice: an update. , 2001, Journal of clinical psychopharmacology.

[39]  J. Gorski,et al.  The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.

[40]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[41]  A. Somogyi,et al.  Pharmacokinetic Interactions of Cimetidine 1987 , 1987, Clinical pharmacokinetics.

[42]  M. Picot,et al.  Effects of interferon-α on cytochrome P‐450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C , 1998 .

[43]  R. Weinshilboum Sulfotransferase pharmacogenetics. , 1990, Pharmacology & therapeutics.

[44]  L. Koymans,et al.  P450 inhibitors of use in medical treatment: focus on mechanisms of action. , 1995, Pharmacology & therapeutics.

[45]  S. Verma,et al.  The Nuclear Factor-κB Pathway Regulates Cytochrome P450 3A4 Protein Stability , 2008, Molecular Pharmacology.

[46]  P. Welling,et al.  Protein Binding of Antimicrobials: Clinical Pharmacokinetic and Therapeutic Implications , 1977, Clinical pharmacokinetics.

[47]  L. Prescott Clinically Important Drug Interactions , 2012, Drugs.

[48]  J. Beijnen,et al.  Pharmacokinetic variability of zidovudine in HIV‐infected individuals: subgroup analysis and drug interactions , 1994, AIDS.

[49]  Biagio Mazzi,et al.  About the Web Site , 2013 .

[50]  F. Russel,et al.  Saturable Pharmacokinetics in the Renal Excretion of Drugs , 1989, Clinical pharmacokinetics.

[51]  C. McClain,et al.  Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. , 1994, The Journal of clinical investigation.

[52]  F. Guengerich,et al.  Role of cytochrome P450 enzymes in drug-drug interactions. , 1997, Advances in pharmacology.

[53]  J. Fagan,et al.  Interleukin-1 beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. , 1992, The Journal of biological chemistry.

[54]  L. Sansom,et al.  What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions? , 1995, Drug safety.

[55]  M. Murray DRUG‐MEDIATED INACTIVATION OF CYTOCHROME P450 , 1997, Clinical and experimental pharmacology & physiology.

[56]  M. Gray,et al.  Pharmacokinetics of drugs that inactivate metabolic enzymes. , 1991, Journal of pharmaceutical sciences.

[57]  A. Goldsobel TERFENADINE-KETOCONAZOLE INTERACTION: PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES , 1994, Pediatrics.

[58]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[59]  A. D. Rodrigues,et al.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.

[60]  K. Renton,et al.  Depression of the hepatic cytochrome P-450 mono-oxygenase system by administered tilorone (2,7-bis(2-(diethylamino)ethoxy)fluoren-9-one dihydrochloride). , 1976, Drug metabolism and disposition: the biological fate of chemicals.

[61]  C. Flexner,et al.  The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive , 1999, Clinical pharmacology and therapeutics.

[62]  K. Korzekwa,et al.  Cytochromes P450 Expression Systems , 1995 .

[63]  M. Strolin Benedetti,et al.  Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. , 1994, Environmental health perspectives.

[64]  G. Bailie,et al.  Quinolone-Cation Interactions: A Review , 1991, DICP : the annals of pharmacotherapy.

[65]  K. Rieckmann,et al.  Quinine disposition during malaria and during induced fever , 1976, Clinical pharmacology and therapeutics.

[66]  A. Jounela [Clinically important drug interactions]. , 1980, Duodecim; laaketieteellinen aikakauskirja.

[67]  D. Middlemas,et al.  Human Immunodeficiency Virus Protease Inhibitors Serve as Substrates for Multidrug Transporter Proteins MDR1 and MRP1 but Retain Antiviral Efficacy in Cell Lines Expressing These Transporters , 1998, Antimicrobial Agents and Chemotherapy.

[68]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[69]  S. Krähenbühl,et al.  Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.

[70]  E. Buchert,et al.  Clinical implications of variable antiarrhythmic drug metabolism. , 1992, Pharmacogenetics.

[71]  G. Garber,et al.  Cations in the didanosine tablet reduce ciprofloxacin bioavailability , 1993, Clinical pharmacology and therapeutics.

[72]  J. Leonard,et al.  Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir * , 1998, Clinical pharmacology and therapeutics.

[73]  P. Macdonald,et al.  Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. , 1995, The New England journal of medicine.

[74]  V. Fischer,et al.  The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. , 1992, The Journal of pharmacology and experimental therapeutics.

[75]  A. Li,et al.  Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. , 1997, Chemico-biological interactions.

[76]  M. Whitelaw,et al.  TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME P450 GENES BY DIFFERENT CLASSES OF CHEMICAL INDUCERS , 1998, Clinical and experimental pharmacology & physiology.

[77]  J. McElnay,et al.  Protein Binding Displacement Interactions and their Clinical Importance , 1983, Drugs.

[78]  D. Greenblatt,et al.  In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.

[79]  F. Vallée,et al.  Effects of Rifabutin and Rifampicin on the Pharmacokinetics of Ethinylestradiol and Norethindrone , 1998, Journal of clinical pharmacology.

[80]  A. Renwick,et al.  Factors affecting the absolute bioavailability of nifedipine. , 1995, British journal of clinical pharmacology.

[81]  Bruce L. Miller,et al.  Office of Technology Assessment Task Force , 1991 .

[82]  K. Ruckpaul,et al.  Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[83]  S. Surapureddi,et al.  Hepatocyte Nuclear Factor 4α Regulates Rifampicin-Mediated Induction of CYP2C Genes in Primary Cultures of Human Hepatocytes , 2010, Drug Metabolism and Disposition.

[84]  J. Graybill,et al.  Itraconazole-didanosine excipient interaction. , 1993, JAMA.

[85]  R. Fontana,et al.  Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[86]  M. Tonini,et al.  Recent advances in the pharmacology of gastrointestinal prokinetics. , 1996, Pharmacological research.

[87]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[88]  W. Stein,et al.  Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. , 1997, Physiological reviews.

[89]  S. Safrin,et al.  Interactions and toxicities of drugs used in patients with AIDS. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  J. Brockmöller,et al.  Assessment of Liver Metabolic Function , 1994, Clinical pharmacokinetics.

[92]  A. Guillouzo,et al.  Caffeine and theophylline metabolism in newborn and adult human hepatocytes; comparison with adult rat hepatocytes. , 1988, Biochemical pharmacology.

[93]  T. Futami,et al.  Effect of clarithromycin on renal excretion of digoxin: Interaction with P‐glycoprotein , 1998, Clinical pharmacology and therapeutics.

[94]  Alessio Fasano,et al.  Tight junction modulation and its relationship to drug delivery. , 2006, Advanced drug delivery reviews.

[95]  E. Morgan,et al.  Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes. , 1997, Biochemical pharmacology.

[96]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[97]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[98]  U. Klotz,et al.  Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.

[99]  U. Christians,et al.  Grapefruit Juice Activates P-Glycoprotein-Mediated Drug Transport , 1999, Pharmaceutical Research.

[100]  Kirby Wm,et al.  Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients. , 1971 .

[101]  B. Tang,et al.  Variability of acetaminophen metabolism in Caucasians and Orientals. , 1992, Pharmacogenetics.

[102]  H. Saitoh,et al.  Restricted Intestinal Absorption of Some β-Lactam Antibiotics by an Energy-Dependent Efflux System in Rat Intestine , 1997, Pharmaceutical Research.

[103]  Leslie Z. Benet,et al.  Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat , 1998, Pharmacology.

[104]  T. Jones The Use of Other Drugs to Allow a Lower Dosage of Cyclosporin to Be Used , 1997, Clinical pharmacokinetics.

[105]  P. Watkins,et al.  Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[106]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[107]  E. Morgan,et al.  Regulation of cytochrome P450IIC12 expression by interleukin-1 alpha, interleukin-6, and dexamethasone. , 1991, Molecular pharmacology.

[108]  P. Statkevich,et al.  Renal Disposition and Drug Interaction Screening of (–)-2′-deoxy-3′-thiacytidine (3TC) in the Isolated Perfused Rat Kidney , 1995, Pharmaceutical Research.

[109]  G. Park,et al.  Failure of critically ill patients to metabolise midazolam , 1987, Anaesthesia.

[110]  M. Rowland Plasma Protein Binding and Therapeutic Drug Monitoring , 1980, Therapeutic drug monitoring.

[111]  R. Polk Drug-drug interactions with ciprofloxacin and other fluoroquinolones. , 1989, The American journal of medicine.

[112]  R. Bendayan Renal Drug Transport: A Review , 1996, Pharmacotherapy.

[113]  Dale J. Kempf,et al.  ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.

[114]  K. Giacomini,et al.  Role of organic cation transporters in drug absorption and elimination. , 1998, Annual review of pharmacology and toxicology.

[115]  S. Krähenbühl,et al.  Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. , 1998, British journal of clinical pharmacology.

[116]  W. Pierson,et al.  Altered theophylline clearance during an influenza B outbreak. , 1982, Pediatrics.

[117]  P. Dogterom Development of a simple incubation system for metabolism studies with precision-cut liver slices. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[118]  C. Regårdh,et al.  Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men , 1997, European Journal of Clinical Pharmacology.

[119]  T. Hidaka,et al.  Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. , 1998, International journal of clinical pharmacology and therapeutics.

[120]  R. Farinotti,et al.  Absorption of ofloxacin isomers in the rat small intestine , 1997, Antimicrobial agents and chemotherapy.

[121]  S. Strom,et al.  Use of human hepatocytes to study P450 gene induction. , 1996, Methods in enzymology.

[122]  E. Morgan Regulation of cytochromes P450 during inflammation and infection. , 1997, Drug metabolism reviews.

[123]  T. D. Bell,et al.  ALTERED THEOPHYLLINE PHARMACOKINETICS DURING ACUTE RESPIRATORY VIRAL ILLNESS , 1978, The Lancet.

[124]  H. Bonkovsky,et al.  Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. , 1985, Gastroenterology.

[125]  T. Ludden Pharmacokinetic Interactions of the Macrolide Antibiotics , 1985, Clinical pharmacokinetics.

[126]  D. Greenblatt,et al.  Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. , 1987, Arzneimittel-Forschung.

[127]  D. Greenblatt,et al.  Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences , 1998, Clinical pharmacology and therapeutics.

[128]  Y. Yazaki,et al.  Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole , 1998, Hematological oncology.

[129]  Ichikawa Yoshiyuki,et al.  Interleukin 2 induction of cytochrome P450-linked monooxygenase systems of rat liver microsomes , 1993 .

[130]  R. Weintraub,et al.  Drug Interactions with Grapefruit Juice , 1997, Clinical pharmacokinetics.

[131]  S. Ekins,et al.  Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[132]  G. Farrell,et al.  Inhibition of antipyrine metabolism by interferon. , 1986, British journal of clinical pharmacology.

[133]  W. Rubas,et al.  A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. , 1997, Critical reviews in therapeutic drug carrier systems.

[134]  R. Barbhaiya,et al.  A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic. , 1997, Biopharmaceutics & drug disposition.

[135]  P. Hansten Drug interactions with antisecretory agents , 1991, Alimentary pharmacology & therapeutics.

[136]  L. Bertilsson,et al.  Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. , 1994, British journal of clinical pharmacology.

[137]  L. Wang,et al.  Human thiopurine S‐methyltransferase (TPMT) pharmacogenetics: Variant allozyme aggresome formation , 2005 .

[138]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[139]  S. Sriwiriyajan,et al.  Effect of omeprazole on the pharmacokinetics of itraconazole , 1998, European Journal of Clinical Pharmacology.

[140]  P. Bonate,et al.  Drug Interactions at the Renal Level , 1998, Clinical pharmacokinetics.

[141]  P. Beaune,et al.  Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. , 1999, Biochemical pharmacology.

[142]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[143]  G. L. Kedderis Pharmacokinetics of drug interactions. , 1997, Advances in pharmacology.

[144]  N. Kitteringham,et al.  Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[145]  C. L. Ferguson,et al.  Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.

[146]  H. Bonkovsky,et al.  Cytochrome P450 of small intestinal epithelial cells , 1985 .

[147]  F. Guengerich,et al.  Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[148]  J. Lettieri,et al.  Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding , 1989, Antimicrobial Agents and Chemotherapy.

[149]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[150]  M. Viitasalo,et al.  Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia , 2004, European Journal of Clinical Pharmacology.

[151]  B. Hasinoff,et al.  Iron supplements: a common cause of drug interactions. , 1991, British journal of clinical pharmacology.

[152]  L. Corcos,et al.  Interleukin‐1β antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture , 1995 .

[153]  O Pelkonen,et al.  Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[154]  Morton B. Brown,et al.  Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. , 1997, The Journal of clinical investigation.

[155]  E. De Clercq,et al.  Carrier Mechanisms Involved in the Transepithelial Transport of bis(POM)-PMEA and Its Metabolites Across Caco-2 Monolayers , 1998, Pharmaceutical Research.

[156]  F. Steinhäuslin,et al.  Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. , 1992, British journal of clinical pharmacology.

[157]  M. Lennard Genetically Determined Adverse Drug Reactions Involving Metabolism , 1993, Drug safety.

[158]  Akira Tsuji,et al.  Carrier-Mediated Intestinal Transport of Drugs , 1996, Pharmaceutical Research.

[159]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[160]  J. Silverman,et al.  Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. , 1998, The Journal of pharmacology and experimental therapeutics.

[161]  D. Sadowski Drug Interactions with Antacids , 1994, Drug safety.

[162]  P. Neuvonen,et al.  Interference of Iron with the Absorption of Tetracylines in Man , 1970, British medical journal.

[163]  P. Neuvonen,et al.  Itraconazole increases plasma concentrations of quinidine , 1997, Clinical pharmacology and therapeutics.

[164]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[165]  G. Wormser,et al.  Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis , 1992, The Lancet.

[166]  G. Farrell,et al.  Rat but not human interferons suppress hepatic oxidative drug metabolism in rats. , 1989, Gastroenterology.

[167]  W. Ritschel Handbook of basic pharmacokinetics , 1976 .

[168]  R. O'Reilly Interaction of sodium warfarin and rifampin. Studies in man. , 1974, Annals of internal medicine.

[169]  Sack Rb Letter: Serotyping of E. coli. , 1976, Lancet.

[170]  P. Welling Interactions Affecting Drug Absorption , 1984, Clinical pharmacokinetics.

[171]  R. Hunt,et al.  Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. , 1990, Gastroenterology.

[172]  J. Miners,et al.  Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[173]  R. Bendayan,et al.  Interaction of 3′‐Azido‐3′‐Deoxythymidine With the Organic Base Transporter in a Cultured Renal Epithelium , 1995, Pharmacotherapy.

[174]  I. Fong,et al.  Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole , 1995, Antimicrobial agents and chemotherapy.

[175]  R. Blouin,et al.  Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. , 1993, British journal of clinical pharmacology.

[176]  D. Greenblatt,et al.  Drug interactions with newer antidepressants: role of human cytochromes P450. , 1998, The Journal of clinical psychiatry.

[177]  A. Y. Lu Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[178]  J. Leyden,et al.  Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. , 1985, Journal of the American Academy of Dermatology.

[179]  R. Weinshilboum Methyltransferase pharmacogenetics. , 1989, Pharmacology & therapeutics.

[180]  T. Seki,et al.  Depression of drug metabolizing activity in the human liver by interferon-α , 2004, European Journal of Clinical Pharmacology.

[181]  H. Dowling,et al.  Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. , 1951, A.M.A. archives of internal medicine.

[182]  R. Parsons,et al.  Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes. , 1975, Journal of Antimicrobial Chemotherapy.

[183]  P. Rolan Plasma protein binding displacement interactions--why are they still regarded as clinically important? , 1994, British journal of clinical pharmacology.

[184]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[185]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[186]  J. Metcalf,et al.  Alteration in Indinavir Clearance During Interleukin‐2 Infusions in Patients Infected with the Human Immunodeficiency Virus , 1998, Pharmacotherapy.

[187]  Shiyin Yee,et al.  In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.

[188]  B. Krevsky,et al.  Regional differences in gastric acidity and antacid distribution: is a single pH electrode sufficient? , 1997, The American journal of gastroenterology.

[189]  S. Spielberg,et al.  N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[190]  Kathy Carroll,et al.  Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes , 2000, Journal of biochemical and molecular toxicology.

[191]  F. Guengerich Characterization of human microsomal cytochrome P-450 enzymes. , 1989, Annual review of pharmacology and toxicology.

[192]  A. Parkinson An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.

[193]  J. Smart,et al.  Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. , 1998, Toxicology letters.

[194]  S. Loft,et al.  Antipyrine clearance in pneumonia , 1985, Clinical pharmacology and therapeutics.